Entry order as a consideration for innovation strategies

Nature Reviews Drug Discovery

Volumn 5, Issue 4, 2006, Pages 285-294

  Cohen, Fredric J ^a  

^a Pharma Growth Strategies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; BIMATOPROST; CANDESARTAN HEXETIL; CELECOXIB; CETIRIZINE; CLOZAPINE; EPROSARTAN; ESOMEPRAZOLE; FEXOFENADINE; FLUOXETINE; LANSOPRAZOLE; LATANOPROST; LORATADINE; MEVINOLIN; OLMESARTAN; OMEPRAZOLE; PANTOPRAZOLE; PAROXETINE; RABEPRAZOLE; RISPERIDONE; ROFECOXIB; SERTRALINE; SILDENAFIL; TADALAFIL; TELMISARTAN; TERFENADINE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER; VALDECOXIB; VARDENAFIL;

AGRANULOCYTOSIS; ARTICLE; COMMERCIAL PHENOMENA; DEPRESSION; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; ERECTILE DYSFUNCTION; GLAUCOMA; HEALTH CARE COST; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PEPTIC ULCER; PRIORITY JOURNAL; PROFIT; QUALITY CONTROL; REIMBURSEMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

COMMERCE; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; ECONOMIC COMPETITION;

EID: 33645469344     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2009     Document Type: Article

References (22)

1. Boulding, W. & Christen, M. Sustainable pioneering advantage? Profit implications of market entry order. Marketing Sci. 22, 317-392 (2003).
2. Narasimhan, C. & Zhang, Z. J. Market entry strategy under firm heterogeneity and asymmetric payoffs. Marketing Sci. 19, 313-327 (2000).
3. Lieberman, M. B. & Montgomery, D. B. First-mover (dis)advantages: retrospective and link with the resource-based view. Strategic Management J. 19, 1111-1125 (1998).
4. Bohlmann, J. D., Golder, P. N. & Mitra, D. Deconstructing the pioneer's advantage: Examining vintage effects and consumer valuations of quality and variety. Management Sci. 48, 1175-1195 (2002).
5. Gittleman, M., ten Raa, T. & Wolff, E. N. The vintage effect in TFP-growth: An analysis of the age structure of capital. National Bureau of Economic Research Working Paper No. 9768 (2003).
6. Carpenter, D. P. & Rynbrandt, R. T. Early entrant protection in U. S. pharmaceutical regulation. Harvard Working Paper [online], (2003).
7. Schmid, E. F. & Smith, D. A. Discovery, innovation and the cyclical nature of the pharmaceutical business. Drug Discov. Today 7, 563-568 (2002).
8. Fischer, M., Leeflang, P. S. H. & Wittink, D. R. Modelling the time to and height of peak sales for pharmaceutical brands. Working paper, University of Kiel (2005).
9. Shankar, V., Carpenter, G. S. &, Lakshman, K. Late-mover advantage: How innovative late entrants outsell pioneers. J. Marketing Res. 35, 54-70 (1998).
10. Fischer, M., Shankar, V. & Clement, M. Does a sound international market entry strategy benefit late movers? Working paper, University of Kiel (2005).
11. Booth, B. L. & Zemmel, R. W. Quest for the best. Nature Rev. Drug Discov. 2, 838-841 (2003).
12. Nordmann, J. P. et al. Unoprostone monotherapy study group-EU. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am. J. Ophthalmol. 133, 1-10 (2002).
13. Rosenberg, J. Head to head struggle: Initial Celebrex, Vioxx ad spending, sales stunning. Advertising Age (03 April 2000).
14. Liebman, M. Head-to-head marketing: May the best promoted drug win. Medical Marketing & Media (01 November 2000).
15. Koerner, B. I. Disorders made to order: Pharmaceutical companies have come up with a new strategy to market their drugs: First go out and find a new mental illness, then push the pills to cure it. Mother Jones (July-August 2002).
16. Levy, B. Consultant's report says 2004 will be pivotal in determining winners and losers in $6 billion ARB hypertension market. Business Wire (28 January 2004).
17. Winslow, R. Wonder drug: Sandoz Corp. 's Clozaril treats schizophrenia but can kill patients - and blood tests to prevent the lethal side effects are costly, controversial - who is going to pay $8,944? Wall Street J. pA1 (14 May 1990).
18. Loew, C. Stimulating innovation in medical technologies. HHS Public Meeting [online], (8 November 2004).
19. Cohen, F. Macro trends in pharmaceutical innovation. Nature Rev. Drug Discov. 4, 78-84 (2005).
20. Accenture & CMR International. Re-thinking innovation in pharmaceutical R&D. [online], (2005).
21. Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571-572 (2002).
22. DiMasi, J. A. & Paquette, C. The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics 22 (Suppl. 2), 1-14 (2004).